# AcuSurgical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acusurgical

- Industry: Medical Devices & Equipment
- Headquarters: Montpellier, France
- Website: www.acusurgical.com
- Total disclosed funding: $3.8M
- Latest round: Series A (Apr 20, 2021)
- Investors on record: 4

## About

AcuSurgical, based in Montpellier, France, specializes in innovative robotic solutions for vitreoretinal surgery, enhancing precision and control during complex ophthalmic procedures.AcuSurgical focuses on developing advanced robotic systems for ophthalmic surgery. Founded in 2020 in Montpellier, France, the company operates under the leadership of CEO Christoph Spuhler and has secured EUR 3.136 mn in Series A funding from investors including Merieux Equity Partners and Supernova Invest as of April 2021. The company has executed a total of 1 deal to date with a current valuation of EUR 7.916 mn.AcuSurgical specializes in advanced robotic solutions tailored for vitreoretinal surgery, with its flagship product being the Luca® robotic platform. Launched in 2020, Luca® assists ophthalmic surgeons by providing enhanced control and stability during intricate procedures, such as repairing retinal detachments and treating macular diseases. The platform is utilized in hospitals and specialized ophthalmic surgical centers across Europe, North America, and select regions in Asia, integrating robotics into traditional surgical practices to elevate standards of care in retinal surgeries.AcuSurgical generates revenue through direct sales of its robotic platform and associated surgical tools, targeting healthcare institutions within a B2B framework. Transaction structures typically involve agreements with hospitals or surgical centers for the acquisition of the Luca® robotic platform. Pricing plans are structured around the acquisition of robotic systems, which may include maintenance and support services to ensure functionality, alongside partnerships for technology integration and training in surgical practices.Following its EUR 3.136 mn Series A funding raised in April 2021, AcuSurgical plans to conduct clinical trials and pursue regulatory approval for its vitreoretinal surgery solutions. The company aims to expand its market presence into new geographic regions by targeting specific areas in Asia and North America by 2023, utilizing the recent funding to support these initiatives.

## Funding rounds

- Series A, Apr 20, 2021, $3.8M — Sofimac Innovation, Merieux Equity Partners, Supernova Invest, Irdi Capital Investissement

## Investors

- Sofimac Innovation (https://capitalatlas.ai/funds/sofimac-innovation) — Series A
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series A
- Supernova Invest (https://capitalatlas.ai/funds/supernova-invest) — Series A
- Irdi Capital Investissement (https://capitalatlas.ai/funds/irdi-capital-investissement) — Series A